Psychiatrist.comInhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depression: A Phase 2a Open-Label Clinical Trial

⚠️ Small Study / Early Comparative Evidence

This phase 2a trial evaluated inhaled GH001, a synthetic mebufotenin formulation, in 10 adults with moderate-to-severe postpartum depression. Patients received up to three escalating doses during one supervised visit. Mean MADRS scores fell 35.4 points by day 8, with response and remission reported in every participant. The magnitude and speed of improvement are notable, but the open-label design, highly selected population, seven-day follow-up, and absence of a comparator prevent conclusions about comparative effectiveness, durability, or routine clinical use.

Clinical Considerations

• All 10 patients reached response and remission by two hours after dosing, and these outcomes persisted through day 8.
• Mean MADRS scores declined approximately 96% from baseline, from 36.7 to an implied mean near 1.3 at the final assessment.
• Maternal functioning improved in the eight evaluable patients, with the BIMF total score increasing by 34.1 points by day 8.
• Eight patients reported treatment-emergent adverse events. Most were mild, headache was most common, and no serious events occurred.
• Psychoactive effects generally lasted approximately 22 to 25 minutes per dose; transient blood-pressure and heart-rate increases resolved spontaneously.
• The study’s single-arm design, 10-patient sample, short follow-up, predominantly White population, sponsor involvement, and restricted concomitant treatment substantially limit interpretation and generalizability.

Practice Applications

• Interpret the findings as hypothesis-generating evidence for rapid symptom improvement, not proof of efficacy against placebo or established treatment.
• Recognize that dosing required supervised administration, psychoactive-effect assessment, physiologic monitoring, psychological support, and formal same-day discharge evaluation.
• Avoid using the preliminary breast-milk measurements to establish breastfeeding safety or a standard interruption interval without further infant-exposure data.
• Discuss GH001 as an investigational intervention distinct from approved postpartum-depression treatments and routine antidepressant management.
• Evaluate future randomized data for durability, relapse, retreatment requirements, maternal functioning, infant outcomes, and use alongside antidepressants or psychotherapy.